Breakthrough Therapies: Market Dynamics and Investment Opportunities
상품코드:1608641
리서치사:BCC Research
발행일:2024년 12월
페이지 정보:영문 114 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 획기적 치료제 시장 규모는 2023년 1,333억 달러, 2024년 1,506억 달러에서 예측기간 동안 CAGR 13.8%로 성장하여 2029년에는 2,875억 달러억 달러에 달할 것으로 예측됩니다.
치료 구분별로는 암 부문이 2024년 821억 달러에서 CAGR 16.6%로 성장하여 2029년에는 1,771억 달러로 성장할 것으로 예측됩니다. 또한 중추신경계 및 신경계 부문은 2024년 149억 달러에서 CAGR 15.4%로 성장하여 2029년에는 304억 달러로 성장할 것으로 예측됩니다.
세계의 획기적 치료제 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 규제 상황, 시장 규모 추정과 예측, 각종 부문·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등을 정리했습니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 개요
제2장 시장 개요
개요
Porter's Five Forces 분석
PESTEL 분석
획기적 치료제 사업 성장에 대한 영향
제3장 시장 역학
시장 역학
시장 성장 촉진요인
획기적 치료제로서 인정되는 의약품 증가
EU의 신속한 승인 프로세스
생명을 위협하는 질환 증가
시장 성장 억제요인
제네릭 의약품에 대한 기호 상승
시장 기회
임상시험에서 기술 이용 증가
제4장 최신 동향
개요
나노기술 : 신약 발견과 전달 강화
Drug Discovery의 기술 융합
결론
제5장 규제 상황
개요
정책
절차
CDER 스폰서 회의 및 기타 커뮤니케이션
CDER의 내부 회의와 커뮤니케이션
CDER의 획기적 치료제 개발 프로그램 리뷰
획기적 치료제 지정 취소
제6장 시장 세분화 분석
세분화 내역
시장 내역 : 치료 구분별
심혈관
중추신경계·신경계
감염증
종양
희귀질환
기타
지역적 내역
시장 내역 : 지역별
북미
유럽
아시아태평양
기타 지역
제7장 경쟁 정보
개요
PRIME 지정 리스트
주요 기업 세계 순위
제8장 BDT 시장의 지속가능성 : ESG 관점
제약 업계에서 ESG의 역할
환경
사회
거버넌스
ESG 리스크 평가
결론
제9장 부록
조사 방법
약어
정보 출처
기업 개요
ABBVIE INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
VERTEX PHARMACEUTICALS INC.
KSM
영문 목차
영문목차
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
The global market for breakthrough therapies for oncology is expected to grow from $82.1 billion in 2024 to $177.1 billion by 2029, at a CAGR of 16.6% from 2024 to 2029.
The global market for breakthrough therapies for CNS and neurology is expected to grow from $14.9 billion in 2024 to $30.4 billion by 2029, at a CAGR of 15.4% from 2024 to 2029.
Report Scope
This report examines the potential risks and benefits of receiving breakthrough therapy designation (BTD), compares and contrasts fast-track drug development approaches (logistics, criteria and implications), and highlights the opportunities and challenges of creating breakthrough therapies. Cardiovascular, central nervous systems and neurology, rare diseases, oncology and other diseases are among the therapy areas in which this report analyzes BTD. It also examines leading companies, approved and pending products, and product revenues. It examines BTD's achievements and shortcomings and discusses the tactics organizations use to optimize BTD's competitive edge.
To provide an in-depth understanding of the market, this report also includes profiles of market participants, the competitive landscape, key competitors and respective market share.
The market in this report is divided into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Includes
26 data tables and 49 additional tables
An overview of the global market dynamics and investment opportunities for breakthrough therapy designation (BTD) drugs
Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
Evaluation and forecast the market size for breakthrough therapies based on type, and geographical region
Discussion of emerging technologies and developments and various macroeconomic factors affecting the breakthrough therapies market
Review of patent data and new developments regarding various categories and sub-categories of breakthrough therapies
A discussion on ESG challenges and practices of the industry
Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews
Information on recent mergers, acquisitions, expansions, collaborations, investments, divestments, product launches, and other strategic developments
Profiles of the leading market vendors, including F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Co., Novartis AG and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Porter's Five Forces Analysis
Potential for New Entrants: High
Bargaining Power of Suppliers: Medium
Bargaining Power of Buyers: Medium
Threat of Substitute Products: High
Industry Competition: High
PESTEL Analysis of the Pharmaceutical Industry
Political Factors
Economic Factors
Social Factors
Technological Factors
Environmental Factors
Legal Factors
Impact of Breakthrough Therapy Drugs on Business Growth
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
More Drugs Gaining Breakthrough Status
Expedited Approval Process in the EU
Increasing Prevalence of Life-Threatening Conditions
Market Restraints
Increasing Preference for Generics
Market Opportunities
Rising Use of Technologies in Clinical Trials
Chapter 4 Emerging Trends
Overview
Nanotechnology: Enhancing Drug Discovery and Delivery
Merging Technologies in Drug Discovery
Conclusion
Chapter 5 Regulatory Landscape
Overview
Policy
Procedures
CDER-Sponsor Meetings and Other Communications
CDER Internal Meetings and Communications
CDER Review of Breakthrough Therapy Drug Development Programs
Rescinding a Breakthrough Therapy Designation
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown by Therapy
Cardiovascular
CNS and Neurology
Infectious Diseases
Oncology
Rare Diseases
Other Diseases
Geographic Breakdown
Market Breakdown by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Overview
PRIME Designation Lists
Global Ranks of Leading Companies
Chapter 8 Sustainability in the BDT Market: An ESG Perspective
